With long-term follow-up, the results of this meta-analysis confirm and extend the results of the published data, showing that BTKis are efficacious in CLL patients with del[11q], del[17p], and/or TP53 mutations because these patients have a generally poor response to CIT [46,47,48]. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.